CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers

This study has been completed.
Information provided by (Responsible Party):
RSPR Pharma AB Identifier:
First received: February 23, 2012
Last updated: October 1, 2012
Last verified: October 2012
This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.

Condition Intervention Phase
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
Drug: CRD007
Phase 2

Study Type: Interventional
Official Title: An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD

Resource links provided by NLM:

Further study details as provided by RSPR Pharma AB:

Arms Assigned Interventions
Experimental: CRD007 10 mg tablet Drug: CRD007


Ages Eligible for Study:   2 Years to 11 Years
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Documented diagnosis of dystrophinopathy

Exclusion Criteria:

  • Severe functional impairment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01540604

Stockholm, Sweden
Sponsors and Collaborators
RSPR Pharma AB
Principal Investigator: T Sejersen, MD PhD Karolinska University Hospital
  More Information

Responsible Party: RSPR Pharma AB Identifier: NCT01540604     History of Changes
Other Study ID Numbers: Cardoz-004 
Study First Received: February 23, 2012
Last Updated: October 1, 2012
Health Authority: Sweden: Medical Products Agency

Keywords provided by RSPR Pharma AB:
symptomatic carriers

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Muscular Diseases
Muscular Disorders, Atrophic
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases processed this record on May 25, 2016